AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

NEXT STORY
The global personal hygiene market was valued at $508.5 billion in 2020 and is projected to reach $720.7 billion by 2030 registering a CAGR of 3.6% from 2021 to 2030
PREV STORY
Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

author_avatar
NASDAQ Market News

Novavax Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Trial of its RSV F Vaccine

Prepare trial is assessing the efficacy of Novavax’ RSV F Vaccine for infants via ...

author_avatar
NASDAQ Market News

Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments

-- Increases KRYSTEXXA®(pegloticase injection) Estimated Peak Annual Net Sales to more than $750 Million ...

author_avatar
NASDAQ Market News